Genomic surgery for lung cancer.
An emerging body of literature indicates that reversible alterations in chromatin structure modulate gene expression during malignant transformation. Chromatin structure is regulated in part by DNA methylation and histone acetylation; these independent yet highly interrelated epigenetic processes are influenced by a variety of signal transduction pathways. The present review highlights recent advances regarding cancer epigenetics, focusing on the potential utilization of chromatin remodeling agents to induce apoptosis and enhance the immunogenicity of thoracic malignancies.
Schrump
David S
DS
Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA. david_Schrump@nih.gov
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D042002:Chromatin Assembly and Disassembly / Q000187:drug effects*; D019175:DNA Methylation; D000077209:Decitabine; D047630:Depsipeptides; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D005818:Genetic Engineering / Q000379:methods*; D006655:Histone Deacetylases; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000628:therapy; D010456:Peptides, Cyclic / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D047630:Depsipeptides; D010456:Peptides, Cyclic; D000077209:Decitabine; C087123:romidepsin; D006655:Histone Deacetylases; D001374:Azacitidine